[HTML][HTML] Noncompletion and nonpublication of trials studying rare diseases: a cross-sectional analysis
Background Rare diseases affect as many as 60 million people in the United States and
Europe. However, most rare diseases lack effective therapies and are in critical need of …
Europe. However, most rare diseases lack effective therapies and are in critical need of …
Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis.
CA Rees, N Pica, MC Monuteaux, FT Bourgeois - PLoS Medicine, 2019 - go.gale.com
Background Rare diseases affect as many as 60 million people in the United States and
Europe. However, most rare diseases lack effective therapies and are in critical need of …
Europe. However, most rare diseases lack effective therapies and are in critical need of …
[HTML][HTML] Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis
CA Rees, N Pica, MC Monuteaux, FT Bourgeois - PLoS Medicine, 2019 - ncbi.nlm.nih.gov
Background Rare diseases affect as many as 60 million people in the United States and
Europe. However, most rare diseases lack effective therapies and are in critical need of …
Europe. However, most rare diseases lack effective therapies and are in critical need of …
Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis
CA Rees, N Pica, MC Monuteaux… - PLOS …, 2019 - econpapers.repec.org
Background: Rare diseases affect as many as 60 million people in the United States and
Europe. However, most rare diseases lack effective therapies and are in critical need of …
Europe. However, most rare diseases lack effective therapies and are in critical need of …
Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis
CA Rees, N Pica, MC Monuteaux… - PLoS …, 2019 - search.proquest.com
Background Rare diseases affect as many as 60 million people in the United States and
Europe. However, most rare diseases lack effective therapies and are in critical need of …
Europe. However, most rare diseases lack effective therapies and are in critical need of …
Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis.
CA Rees, N Pica, MC Monuteaux, FT Bourgeois - Plos Medicine, 2019 - europepmc.org
Background Rare diseases affect as many as 60 million people in the United States and
Europe. However, most rare diseases lack effective therapies and are in critical need of …
Europe. However, most rare diseases lack effective therapies and are in critical need of …
Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis
CA Rees, N Pica, MC Monuteaux… - PLoS …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Rare diseases affect as many as 60 million people in the United States and
Europe. However, most rare diseases lack effective therapies and are in critical need of …
Europe. However, most rare diseases lack effective therapies and are in critical need of …
[PDF][PDF] Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis
CA Rees, N Pica, MC Monuteaux… - PLoS …, 2019 - pdfs.semanticscholar.org
Background Rare diseases affect as many as 60 million people in the United States and
Europe. However, most rare diseases lack effective therapies and are in critical need of …
Europe. However, most rare diseases lack effective therapies and are in critical need of …
Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis
CA Rees, N Pica, MC Monuteaux, FT Bourgeois - PLOS Medicine, 2019 - ideas.repec.org
Background: Rare diseases affect as many as 60 million people in the United States and
Europe. However, most rare diseases lack effective therapies and are in critical need of …
Europe. However, most rare diseases lack effective therapies and are in critical need of …